10X Genomics Inc (TXG)vsVeeva Systems Inc Class A (VEEV)
TXG
10X Genomics Inc
$20.91
+5.55%
HEALTHCARE · Cap: $2.53B
VEEV
Veeva Systems Inc Class A
$178.11
-0.56%
HEALTHCARE · Cap: $29.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Veeva Systems Inc Class A generates 397% more annual revenue ($3.20B vs $642.82M). VEEV leads profitability with a 28.4% profit margin vs -6.8%. VEEV earns a higher WallStSmart Score of 69/100 (B-).
TXG
Avoid32
out of 100
Grade: F
VEEV
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for TXG.
Margin of Safety
+25.9%
Fair Value
$238.92
Current Price
$178.11
$60.81 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Keeps 28 of every $100 in revenue as profit
Growing faster than its price suggests
Strong operational efficiency at 29.4%
16.0% revenue growth
Earnings expanding 23.2% YoY
Areas to Watch
0.6% revenue growth
0.0% earnings growth
ROE of -5.8% — below average capital efficiency
Currently unprofitable
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : TXG
TXG has a balanced fundamental profile.
Bull Case : VEEV
The strongest argument for VEEV centers on Debt/Equity, Profit Margin, PEG Ratio. Profitability is solid with margins at 28.4% and operating margin at 29.4%. Revenue growth of 16.0% demonstrates continued momentum.
Bear Case : TXG
The primary concerns for TXG are Revenue Growth, EPS Growth, Return on Equity.
Bear Case : VEEV
The primary concerns for VEEV are P/E Ratio.
Key Dynamics to Monitor
TXG profiles as a turnaround stock while VEEV is a growth play — different risk/reward profiles.
TXG carries more volatility with a beta of 2.21 — expect wider price swings.
VEEV is growing revenue faster at 16.0% — sustainability is the question.
VEEV generates stronger free cash flow (100M), providing more financial flexibility.
Bottom Line
VEEV scores higher overall (69/100 vs 32/100), backed by strong 28.4% margins and 16.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
10X Genomics Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.
Veeva Systems Inc Class A
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?